The Food and Drug Administration (FDA) surprisingly approved insulin degludec injection (Tresiba) and insulin degludec/insulin aspart injection (Ryzodeg) 70/30. Pharmacist and CDE Sam Grossman discusses some of the clinical trial findings for the medicines and offers some clinical prescribing guidance.
Chronic usage of metformin, the first-line type 2 medicine, can cause vitamin B12 deficiencies in many people. Sam Grossman talks about what is in the medical literature about this topic and offers some advice to avoid a deficiency in this essential vitamin.
A new study reports that Jardiance reduces the risk of acute cardiovascular episodes including heart attacks and strokes. Certified diabetes educator Sam Grossman looks at the study and provides analysis.
Dr. Sam Grossman looks at statin use in people at risk for diabetes and discusses the risks versus the benefits.
Poor adherence to medical treatment is widespread and well recognized. Here are seven tips to help you adhere to your proper medication usage while on vacation.
According to a study that was published in the New England Journal of Medicine, this class of drugs did not increase the risk for cardiovascular events, which was previously discussed and a concern in the medical community.
Sam Grossman provides some information on the recently approved 200 unit/mL formulation of Eli Lilly and Company’s pre-filled pen containing insulin lispro (Humalog U-200 KwikPen).
Genentech’s drug Avastin is used to treat cancer, but has also been used off-label for treatment of eye disease including diabetic retinopathy (DR). Sam Grossman discusses some of the studies’ findings of this medicine and whether people with DR may want to inquire with their healthcare providers about it.
Certified diabetes educator Amy Hess-Fischl talks about using GLP-1 agonists off-label in people with type 1 and shares some anecdotal evidence from patients as well as studies using this drug class in this patient population.
An FDA Panel recommends new safety information on DPP-4 inhibitors Onglyza and Nesina. Sam Grossman reviews this news and how it may affect marketing and prescribing of the medications.
Sanofi’s recently approved insulin, Toujeo, is 300u/ml and offers clinicians and people with diabetes who have glycemic control issues another long-acting insulin. Sam Grossman discusses some of the studies’ findings.
The FDA recently approved Lucentis for use of diabetic retinopathy. Pharmacist and certified diabetes educator Sam Grossman talks about the clinical trial results for the new drug and considerations of how people with the complication may want to consider talking to their provider about it.
Diabetes educator Debbie Berg discusses some strategies to make it easier to keep up with your regular regimen of medicine.
The FDA approved the inhaled insulin, Afrezza, last summer, and it will likely undergo a massive marketing campaign to providers and possibly to people with diabetes directly. Here is some important clinical trial information about the medicine and how it is indicated for use in patients.
